| Literature DB >> 17176575 |
Kimberley S M Benschop1, Janke Schinkel, Manon E Luken, Peter J M van den Broek, Matthias F C Beersma, Negassi Menelik, Hetty W M van Eijk, Hans L Zaaijer, Christina M J E VandenBroucke-Grauls, Marcel G H M Beld, Katja C Wolthers.
Abstract
We identified a novel human parechovirus (HPeV) type (K251176-02) from a neonate with fever. Analysis of the complete genome showed K251176-02 to be a new HPeV genotype. Since K251176-02 could not be neutralized with antibodies against known HPeV serotypes 1-3, it should be classified as a fourth HPeV serotype.Entities:
Mesh:
Year: 2006 PMID: 17176575 PMCID: PMC3290933 DOI: 10.3201/eid1210.051647
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Unrooted phylogenetic trees showing the relationship between K251176-02 (DQ315670) and the prototype strains human parechovirus serotype 1 (HPeV1) Harris (S45208), HPeV2 Williamson (AJ005695), HPeV2 CT86-6760 (AF055846), HPeV3 A308-99 (AB084913), and Can82853-01 (AJ889918) based on nucleotide Jukes and Cantor substitution model for the capsid region (A) and the nonstructural region (B). The tree was constructed by the neighbor-joining method as implemented in MEGA version 3.1. Gaps introduced for optimal alignment were not considered informative and were excluded from the analyses by complete deletion. Numbers represent the frequency of occurrence of nodes in 1,000 bootstrap replicas. The use of other evolution models did not influence the tree topology.
Figure 2Similarity plot of human parechovirus serotype 1 (HPeV1) Harris (S45208), HPeV2 Williamson (AJ005695), HPeV2 CT86-6760 (AF055846), HPeV3 A308-99 (AB084913), and Can82853-01 (AJ889918) against K251176-02. Each curve is a comparison between the K251176-02 genome and an HPeV prototype. Each point represents the percentage identity within a sliding window 600 bp wide, centered on the position plotted, with a step size of 20 bp. Positions containing gaps were excluded from the comparison by gap stripping, and Jukes and Cantor correction was applied. Similarity plots of the full-length sequences of the HPeV prototypes were generated by using SimPlot version 2.5.
Amino acid identity matrix of all known human parechovirus (HPeV) full-length sequences*
| Target | HPeV1 (H) | HPeV2 (W) | HPeV2 (CT) | HPeV3 (A308) | HPeV3 (Can) | |
|---|---|---|---|---|---|---|
| ORF | ||||||
| K251176-02 | 88.7 | 86.9 | 90.1 | 89.1 | 89.3 | |
| HPeV1 (H) | – | 88.6 | 88.1 | 87.2 | 87.3 | |
| HPeV2 (W) | – | – | 85.8 | 85.1 | 85.0 | |
| HPeV2 (CT) | – | – | – | 86.7 | 86.9 | |
| HPeV3 (A308) | – | – | – | – | 98.2 | |
| HPeV3 (Can) | – | – | – | – | – | |
| P1 | ||||||
| K251176-02 | 78.3 | 78.6 | 81.3 | 74.7 | 75.1 | |
| HPeV1 (H) | – | 81.6 | 76.4 | 74.9 | 75.3 | |
| HPeV2 (W) | – | – | 74.2 | 73.9 | 73.9 | |
| HPeV2 (CT) | – | – | – | 73.0 | 73.5 | |
| HPeV3 (A308) | – | – | – | – | 97.4 | |
| HPeV3 (Can) | – | – | – | – | – | |
| P2-P3 | ||||||
| K251176-02 | 94.3 | 91.5 | 94.9 | 97.0 | 97.1 | |
| HPeV1 (H) | – | 92.4 | 94.5 | 93.8 | 93.9 | |
| HPeV2 (W) | – | – | 92.2 | 91.2 | 91.1 | |
| HPeV2 (CT) | – | – | – | 94.2 | 94.2 | |
| HPeV3 (A308) | – | – | – | – | 98.6 | |
| HPeV3 (Can) | – | – | – | – | – | |
*Amino acid identities for the open reading frame (ORF), capsid region (P1), and nonstructural region (P2-P3) are based on p-distance models between K251176-02 (DQ315670) and the HPeV prototypes, HPeV1 (H) (Harris, S45208), HPeV2 (W) (Williamson, AJ005695), HPeV2 (CT) (CT86-6760, AF055846), HPeV3 (A308) (A308-99, AB084913), and HPeV3 (Can) (Can82853-01, AJ889918). The full-length sequence of K251176-02 was aligned with the HPeV prototypes by using ClustalW, included in the Vector NTI Advance 10 software package (Invitrogen, Carlsbad, CA, USA). Alignment was edited by using GeneDoc software (version 2.6.02). The matrix was constructed by using MEGA version 3.1. The 5´ untranslated region (UTR) and 3´ UTR are excluded from the analysis because the regions are noncoding.
Neutralization assay with LLcMk2 cells*
| Virus | Antiserum | Viral controls | ||
|---|---|---|---|---|
| a-HPeV1 (Harris) | a-HPeV2 (Williamson) | a-HPeV3 (A308-99) | ||
| HPeV1 Harris | – | ++++ | ++++ | ++++ |
| HPeV2 Williamson | ++++ | – | ++++ | ++++ |
| K251181-02 (HPeV3) | ++++ | ++++ | – | ++++ |
| K251176-02 | ++++ | ++++ | ++++ | ++++ |
*Culture isolates of K251176-02, human parechovirus 1 (HPeV1, echovirus 22) and HPeV2 (echovirus 23) from a reference panel (National Institute for Public Health and the Environment, Bilthoven, the Netherlands) and K251181-02 that was previously genotyped as HPeV3 () were incubated with antisera (20 U/mL in Eagle minimal essential medium) directed against HPeV1 Harris, HPeV2 Williamson, and HPeV3 A308-99. The antisera to HPeV1 and HPeV2 were raised in horses. The antiserum to HPeV3 was raised in guinea pigs. Neutralization is done on a 96-microtiter plate containing a monolayer of LLcMk2 cells that have been incubated for 3 days. The assay was determined after viral controls (no antisera used) of the 4 culture isolates showed cytopathic effects >50% (++++).